InterMune, Inc. (NASDAQ:ITMN)

CAPS Rating: 2 out of 5

The Company is a biotech company focused on developing and commercializing innovative therapies in pulmonology and hepatology.

Results 1 - 20 of 38 : 1 2 Next »

Recs

0
Member Avatar pchop123 (78.34) Submitted: 4/17/2014 1:40:03 PM : Outperform Start Price: $28.82 ITMN Score: +0.50

has factual based promise

Recs

1
Member Avatar zzlangerhans (99.74) Submitted: 3/13/2014 10:27:45 PM : Outperform Start Price: $33.73 ITMN Score: -13.52

I suppose I could do a discounted cash flow analysis for Intermune, factoring in the probabilities of different reimbursement levels for pirfenidone in the US and potential competition from nintedanib if Boehringer reports positive data from the INPULSIS trials in May. Then again, I could just wing it and spend that time playing on the Ipad with my daughter instead. No contest, really. Based on the way I've seen this stock behave over the last seven years, I see the share price reaching at least 36 some time before the ATS conference in mid-May. My level of confidence isn't enough to get me to buy in at a share price of 33 for a potential 10% gain, but if the stock were to decline below 30 and stabilize I would likely make Intermune a small part of the zzporte portfolio.

Recs

0
Member Avatar ResearchLover (46.93) Submitted: 2/26/2014 11:11:09 AM : Outperform Start Price: $33.78 ITMN Score: -14.98

ASCEND trial results are definitive for FDA approval this time.

Recs

0
Member Avatar AndrewGreenBull (99.32) Submitted: 2/26/2014 9:00:15 AM : Outperform Start Price: $35.83 ITMN Score: -20.05

$50 again, next blockbuster

Recs

0
Member Avatar damoninak (89.67) Submitted: 2/26/2014 1:40:28 AM : Outperform Start Price: $35.83 ITMN Score: -20.05

It's awesome

Recs

0
Member Avatar tad40 (99.71) Submitted: 2/25/2014 3:19:39 PM : Underperform Start Price: $37.17 ITMN Score: +23.21

TOO MUCH, TOO QUICK

Recs

1
Member Avatar SkepBioInvestor (88.93) Submitted: 2/9/2014 1:30:59 PM : Outperform Start Price: $12.44 ITMN Score: +128.83

Positive ASCEND data

Recs

1
Member Avatar HIGHG33K (73.93) Submitted: 2/4/2014 12:21:59 AM : Outperform Start Price: $12.16 ITMN Score: +131.37

great value

Recs

0
Member Avatar MKArch (99.71) Submitted: 4/21/2013 10:00:28 AM : Outperform Start Price: $8.99 ITMN Score: +201.87

One Pipeline drug; binary proposition, that I'm taking a shot on based on M* analysis. Don't bet anything you can't afford to lose on this one.

Recs

0
Member Avatar SnarkyApple (34.90) Submitted: 9/17/2012 4:08:56 PM : Outperform Start Price: $9.69 ITMN Score: +171.32

Shenanigans.

Recs

0
Member Avatar ghall3 (< 20) Submitted: 4/23/2012 7:19:15 AM : Outperform Start Price: $9.94 ITMN Score: +157.85

Lower price caused by essentially deferring profit to the future, but the profit will be there. Same thing that happened to them a few years ago.

Recs

0
Member Avatar SorrySam (73.55) Submitted: 4/21/2012 2:54:57 AM : Outperform Start Price: $12.12 ITMN Score: +102.13

qvt financial who made blockbuster calls on mdvn, inhx, etc.

Recs

0
Member Avatar EclecticRecluse (78.43) Submitted: 3/23/2011 7:41:55 AM : Underperform Start Price: $43.86 ITMN Score: +78.79

Low Sales and Few Employees for Capital

Recs

0
Member Avatar bg019818 (< 20) Submitted: 12/31/2010 9:18:42 AM : Outperform Start Price: $36.78 ITMN Score: -70.01

Breakthrough in its lung disease drug.

Recs

0
Member Avatar diansacc (< 20) Submitted: 12/27/2010 5:14:57 PM : Underperform Start Price: $38.01 ITMN Score: +72.12

itmn

Recs

0
Member Avatar flipsmurf (71.70) Submitted: 6/14/2010 5:04:23 PM : Outperform Start Price: $9.75 ITMN Score: +127.64

Great new product and way oversold at current price

Recs

0
Member Avatar aldebaranccs (< 20) Submitted: 6/11/2010 3:49:56 PM : Outperform Start Price: $9.53 ITMN Score: +133.49

bull

Recs

0
Member Avatar jkok (48.43) Submitted: 5/6/2010 9:54:29 AM : Outperform Start Price: $13.01 ITMN Score: +62.66

recently suffered

Recs

1
Member Avatar BlackshearFund (< 20) Submitted: 5/5/2010 7:30:47 PM : Outperform Start Price: $10.06 ITMN Score: +127.61

Oversold. Might see 15's again soon.

Recs

0
Member Avatar Zolton7620 (< 20) Submitted: 3/23/2010 3:28:50 AM : Outperform Start Price: $40.95 ITMN Score: -89.20

The drug pirfenidone now under consideration by the FDA for approval for treatment of Idiopathic Pulmonary Function is also effective for MS and a number of other diseases yet to be fully tested.

Results 1 - 20 of 38 : 1 2 Next »

Featured Broker Partners


Advertisement